Results 241 to 250 of about 296,123 (303)

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source

TEVAR-Only Management of Abdominal Aortic Aneurysm Rupture Caused by Acute Type B Aortic Dissection after EVAR: A Case Report. [PDF]

Ann Vasc Dis
Takahashi T, Namura O, Mimura S.
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Granulomatous Lung Inflammation of Unknown Causes Following COVID-19. [PDF]

Cureus
Watanabe K, Kaneko T.
europepmc   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source

Quantitative assessment of thoracic morphometry in interstitial lung diseases: a CT-based comparison of nonspecific interstitial pneumonia, usual interstitial pneumonia, and healthy control. [PDF]

Pol J Radiol
Er Ulubaba H, Deniz G.
europepmc   +1 more source

METASTATIC ANGIOSARCOMA PRESENTING AS HAEMOPTYSIS AND SEVERE PAIN ON THE BACK

, 2021
Caglar, Emel, Ortakoylu, Mediha G., Aslan, Ceyda, Kara, Asuman, Taskin, Orhun C., Bahadir, Ayse, Alkan, Figen, Ar, Cem   +7 more
core  

Hypertrophic Osteopathy Associated With Primary Pulmonary Histiocytic Sarcoma in a Dog. [PDF]

Vet Med Sci
Rinaldi V, Ridolfi F, Finotello R, Rosto M, Luciani A, Boari A, Crisi PE.   +6 more
europepmc   +1 more source

Mediastinal Chyloma after Ascending Aortic Replacement: A Case of Delayed, Localized Chyle Leakage. [PDF]

Ann Vasc Dis
Yamakawa M, Yokote J, Kurokawa K, Marutani T, Shibahara H, Yamamoto T, Ashida S, Mutsuga M.   +7 more
europepmc   +1 more source

New opportunities for bioscaffold‐enabled spinal cord injury repair

BMEMat, EarlyView.
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi, Yicheng Fu, Zhaoliang Su, Li Li, Subrata Chakrabarti, Peng Li, Yilun Wu, Fang Liu, Teng Gao, Zhifeng Dong, Lei Liu, Pei Cao   +11 more
wiley   +1 more source